Barclays
CGEM icon

Barclays’s Cullinan Oncology CGEM Stock Holding History

Barclays’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.73M Buy
177,595
+33,650
+23% +$644K ﹤0.01% 2409
2026
Q2 		$2.62M Buy
143,945
+3,650
+3% +$54.2K ﹤0.01% 2208
2026
Q1 		$1.99M Sell
140,295
-129,360
-48% -$1.66M ﹤0.01% 2356
2025
Q4 		$2.79M Buy
269,655
+18,545
+7% +$167K ﹤0.01% 2682
2025
Q3 		$1.49M Sell
251,110
-17,357
-6% -$127K ﹤0.01% 3107
2025
Q2 		$2.02M Buy
268,467
+27,124
+11% +$218K ﹤0.01% 2837
2025
Q1 		$1.83M Sell
241,343
-3,888
-2% -$37.3K ﹤0.01% 2699
2024
Q4 		$2.99M Sell
245,231
-3,383
-1% -$48.6K ﹤0.01% 2591
2024
Q3 		$4.16M Buy
248,614
+51,300
+26% +$910K ﹤0.01% 2249
2024
Q2 		$3.44M Buy
197,314
+157,122
+391% +$3.35M ﹤0.01% 1766
2024
Q1 		$685K Sell
40,192
-45,032
-53% -$696K ﹤0.01% 3388
2023
Q4 		$868K Buy
85,224
+31,831
+60% +$282K ﹤0.01% 3542
2023
Q3 		$483K Buy
53,393
+31,650
+146% +$330K ﹤0.01% 2829
2023
Q2 		$234K Sell
21,743
-6,570
-23% -$69.8K ﹤0.01% 3170
2023
Q1 		$290K Buy
28,313
+6,817
+32% +$75.2K ﹤0.01% 3595
2022
Q4 		$227K Buy
21,496
+12,502
+139% +$152K ﹤0.01% 3771
2022
Q3 		$116K Buy
8,994
+1,731
+24% +$23.3K ﹤0.01% 3479
2022
Q2 		$93K Sell
7,263
-65
-0.9% -$737 ﹤0.01% 3793
2022
Q1 		$77K Buy
+7,328
New +$99K ﹤0.01% 3909

Other funds holding CGEM

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Ellsworth Advisors
Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Barclays's CGEM Position: Q3 2026 in Review

Barclays increased its Cullinan Oncology (CGEM) stake by 23% in Q3 2026, buying an estimated $644K and bringing the position to 177,595 shares worth $2.73M. The position accounts for ﹤0.01% of the portfolio, ranked #2409.

Barclays first reported a position in CGEM in Q1 2022 and has held it in 19 quarters since. The position peaked at $4.16M in Q3 2024. 55 funds tracked by Wall St. Rank hold CGEM as of Q3 2026.

  • Barclays held 177,595 shares of Cullinan Oncology worth $2.73M as of Q3 2026.
  • Barclays bought 33,650 Cullinan Oncology shares in Q3 2026, an estimated $644K.
  • Cullinan Oncology made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2409 holding.
  • Barclays first reported a position in Cullinan Oncology in Q1 2022 and has held it in 19 quarters since.
  • Barclays's Cullinan Oncology position peaked at $4.16M in Q3 2024.
  • 55 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.